{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:04:19Z","timestamp":1768809859473,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.jaad.2008.10.043","type":"journal-article","created":{"date-parts":[[2009,8,27]],"date-time":"2009-08-27T06:17:33Z","timestamp":1251353853000},"page":"522-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["The histologic spectrum of epithelial neoplasms induced by sorafenib"],"prefix":"10.1016","volume":"61","author":[{"given":"Eun Ji","family":"Kwon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Stephen","family":"Kish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Jaworsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2008.10.043_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.10.043_bib2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.10.043_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2006.10.032","article-title":"Keratoacanthomas associated with sorafenib therapy","volume":"56","author":"Kong","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.10.043_bib4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archderm.144.6.779","article-title":"Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib","volume":"144","author":"Hong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.10.043_bib5","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","article-title":"Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors","volume":"12","author":"Strumberg","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2008.10.043_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2008.10.043_bib7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/SMJ.0b013e31802f01a9","article-title":"Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma","volume":"100","author":"Dasanu","year":"2007","journal-title":"South Med J"},{"key":"10.1016\/j.jaad.2008.10.043_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.10.043_bib9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/107327480901600110","article-title":"Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene","volume":"16","author":"Marquez","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.jaad.2008.10.043_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3816\/CGC.2009.n.003","article-title":"Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib","volume":"7","author":"Dubauskas","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.jaad.2008.10.043_bib11","first-page":"326","article-title":"Keratoacanthoma: a clinico-pathologic enigma","volume":"30","author":"Schwartz","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2008.10.043_bib12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/1097-0142(196305)16:5<603::AID-CNCR2820160510>3.0.CO;2-9","article-title":"The etiology of keratoacanthoma","volume":"16","author":"Ghadially","year":"1963","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.10.043_bib13","first-page":"804","article-title":"Development of a keratoacanthoma after topical photodynamic therapy with 5-aminolevulinic acid","volume":"5","author":"Maydan","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2008.10.043_bib14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2340\/00015555-0109","article-title":"Multiple keratoacanthomas as an untoward response to imiquimod therapy for actinic keratoses","volume":"86","author":"D'Addario","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2008.10.043_bib15","first-page":"680","article-title":"Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine","volume":"3","author":"Lain","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2008.10.043_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/archderm.1992.01680110085011","article-title":"Suramin-induced skin reactions","volume":"128","author":"O'Donnell","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.10.043_bib17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/archderm.1996.03890250110027","article-title":"Keratoacanthomas and skin neoplasms associated with suramin therapy","volume":"132","author":"Kobayashi","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.10.043_bib18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0190-9622(83)70181-7","article-title":"Multiple keratoacanthomas possibly induced by psoralens and ultraviolet A photochemotherapy","volume":"9","author":"Sina","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.10.043_bib19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/120347540400800407","article-title":"Multiple keratoacanthomas arising post-UVB therapy","volume":"8","author":"Craddock","year":"2004","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2008.10.043_bib20","first-page":"201","article-title":"Rapid development of keratoacanthomas after a body peel","volume":"29","author":"Cox","year":"2003","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2008.10.043_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/1097-0142(197801)41:1<12::AID-CNCR2820410104>3.0.CO;2-7","article-title":"Rapid development of keratoacanthoma and accelerated transformation into squamous cell carcinoma of the skin: a mutagenic effect of polychemotherapy in a patient with Hodgkin's disease?","volume":"41","author":"Poleksic","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.10.043_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2230.2006.02223.x","article-title":"Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor","volume":"31","author":"Lacouture","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2008.10.043_bib23","doi-asserted-by":"crossref","first-page":"9304","DOI":"10.1158\/0008-5472.CAN-07-0798","article-title":"Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib","volume":"67","author":"Timpson","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2008.10.043_bib24","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1158\/0008-5472.CAN-04-2118","article-title":"Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor","volume":"65","author":"Timpson","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2008.10.043_bib25","doi-asserted-by":"crossref","first-page":"7764","DOI":"10.1158\/1078-0432.CCR-04-0012","article-title":"Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines","volume":"10","author":"Kalish","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2008.10.043_bib26","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1158\/1078-0432.CCR-05-2404","article-title":"Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells","volume":"12","author":"Erjala","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2008.10.043_bib27","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ejcb.2006.11.002","article-title":"The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1","volume":"86","author":"Burnworth","year":"2007","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.jaad.2008.10.043_bib28","first-page":"973","article-title":"HER3 expression in cutaneous tumors","volume":"28","author":"Wimmer","year":"2008","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jaad.2008.10.043_bib29","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/DAD.0b013e318159bf95","article-title":"HER2 and EGFR expression in cutaneous spindle squamous cell carcinoma","volume":"29","author":"Schlauder","year":"2007","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2008.10.043_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-0560.1992.tb01561.x","article-title":"Abnormal expression of epidermal growth factor receptor in cutaneous epithelial tumors","volume":"19","author":"Groves","year":"1992","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2008.10.043_bib31","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.1073\/pnas.0510284103","article-title":"Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors","volume":"103","author":"Ji","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2008.10.043_bib32","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/JTO.0b013e3181654423","article-title":"Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC)","volume":"3","author":"Brueckl","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jaad.2008.10.043_bib33","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-07-4905","article-title":"Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells","volume":"14","author":"Bianco","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2008.10.043_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0002-9440(10)64715-3","article-title":"Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas","volume":"156","author":"Detmar","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2008.10.043_bib35","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/jcb.21920","article-title":"Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF","volume":"105","author":"Tong","year":"2008","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.jaad.2008.10.043_bib36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mc.2940040306","article-title":"N ras gene mutation and amplification in human non-melanoma skin cancers","volume":"4","author":"Pierceall","year":"1991","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.jaad.2008.10.043_bib37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/1523-1747.ep12874504","article-title":"Ras oncogene mutations in basal cell carcinomas and squamous cell carcinomas of human skin","volume":"94","author":"van der Schroeff","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2008.10.043_bib38","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/jid.2008.427","article-title":"Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma","volume":"129","author":"Arbiser","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2008.10.043_bib39","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/archderm.1995.01690190048009","article-title":"Activated ras genes occur in human actinic keratoses, premalignant precursors to SCCs","volume":"131","author":"Spencer","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.10.043_bib40","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1182\/blood-2007-02-075945","article-title":"Sorafenib but not sunitinib affects the function of dendritic cells and the induction of primary immune responses","volume":"111","author":"Hipp","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2008.10.043_bib41","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/leu.2008.58","article-title":"Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation","volume":"22","author":"Zhao","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jaad.2008.10.043_bib42","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.seminoncol.2006.04.002","article-title":"Role of Raf kinase in cancer: therapeutic potential of targeting the Raf\/MEK\/ERK signal transduction pathway","volume":"33","author":"Gollob","year":"2006","journal-title":"Semin Oncol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962208013716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962208013716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:13:47Z","timestamp":1759270427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962208013716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0190962208013716"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2008.10.043","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The histologic spectrum of epithelial neoplasms induced by sorafenib","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2008.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}